Changchun high -tech crash, Grand was dragged again?Company response: normal operation

On August 18, Changchun High -tech (000661.SZ) fell in the afternoon. The company's stock price fell from 215 yuan/share to 202.1 yuan/share within more than ten minutes. As of the close, the company's total market value was 81.79 billion yuan.

↑ Screenshots of the closure

In response to this, the staff of the Changchun High -tech Director Office told the Red Star Capital Bureau that the company's operations were normal and there was no "Zhuang stock" or manipulating the stock price.

As for why the stock price was diving, the staff of the director office stated that it was reported that Zhejiang Province released the third batch of drug collection for soliciting comments. Investors were more concerned about this and worried that it would have a greater impact on the company.

The staff of the Zhejiang Province, the staff referred to, is the "Third Batch of Pharmaceutical Collection Purchasing Purchasing Documents in Zhejiang Public Medical Institutions" (soliciting opinion draft) issued by Zhejiang Pharmaceutical Procurement Center on August 17. From August 17th to 23rd, the Red Star Capital Bureau noticed that the discussion draft did not list any company or medicine.

The staff of the Changchun High -tech Directors also said that the document is a draft for comments and does not give a specific list of enterprises and products. "I don't know how everyone interprets it, but so far, the company can only keep attention at the level of the company."

In fact, at the beginning of this year, Changchun High -tech fell due to the collection of pharmaceutical collection.

On January 19, 2022, the Guangdong Pharmaceutical Exchange Center released a message to confirm that the reorganized human growth hormone was included in the Guangdong Collection Alliance, and the episode made the highest price for reorganized human growth hormones.

Affected by the above -mentioned collection of news, Changchun High -tech closed three limits. Based on the closing price on January 18, as of January 21, the stock price of Changchun High -tech fell nearly 30 % within three days. (For details, please poke: "Changchun High -tech Directors shouted" Cangtian ", major shareholders may face explosive positions, and the second shareholders have cash out 3.8 billion")

In response to the Guangdong collection, the staff of the Changchun High -tech Director Office said: "Guangdong and Zhejiang are the collection of collecting and mining in different provinces. The specific provisions and rules of the documents are different, and there is no comparison. Seeing the measures is very positive. "

The Red Star Capital Bureau noticed that many investors also mentioned Gelan, a public fund manager of Changchun Changchun High -tech on social platforms, and questioned the public fund managed by Gram's management may face a decline in income.

↑ Investors also leave a screenshot

Changchun High -tech annual reports showed that Gram -managed China -Europe Medical and Healthy Securities Investment Fund (hereinafter referred to as "China -Europe Medical") managed by Gram is the top 10 shareholders, holding 1.48%of the shares. However, in the first quarterly report of 2022, China -Europe Medicalcare is no longer among the top ten shareholders.

In addition, according to the second quarter report of China -Europe Medical in 2022, as of the end of June 2022, it was sorted by the net value ratio of the fund assets according to the fair value.

↑ China -Europe Medical Healthy Hybrid Securities Investment Fund 2022 second quarter report

In addition, the Grandan Research Selection of Mixed Securities Investment Fund in the second quarter of 2022 also shows that Changchun High -tech is not among the top ten stock investment.

Red Star News reporter Yu Yao Tao Yanyang

Edit Yu Dongmei Yang Cheng

- END -